OmniAb (OABI) Return on Invested Capital (2022 - 2026)
OmniAb's (OABI) quarterly Return on Invested Capital came in at 0.16% in Q1 2026, up 16.0% year-on-year from 0.14% in Q1 2025, and up 29.29% on a QoQ basis from 0.23% in Q4 2025.
OmniAb (OABI) Return on Invested Capital (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Return on Invested Capital data on file, last reported at 0.16% in Q1 2026.
- On a quarterly basis, Return on Invested Capital rose 16.0% year-over-year to 0.16% in Q1 2026; TTM through Mar 2026 was 0.16%, a 16.0% increase from a year earlier, with the FY2025 full-year figure at 0.86%, down 15.0% from the prior year.
- Return on Invested Capital for Q1 2026 stood at 0.16%, up from 0.23% in the prior quarter.
- Over the last five years, Return on Invested Capital for OABI reached as high as 0.03% in Q3 2023 and fell as low as 0.32% in Q1 2025.
- Historically, Return on Invested Capital has averaged 0.15% across 5 years, with a median of 0.14% in 2024.
- Across the five-year window, Return on Invested Capital dropped 23 bps in 2025 and gained 16 bps in 2026, its largest moves.
- Year by year, Return on Invested Capital stood at 0.07% in 2022, then rose by 14 bps to 0.06% in 2023, then tumbled by 334 bps to 0.24% in 2024, then rose by 8 bps to 0.23% in 2025, then advanced by 29 bps to 0.16% in 2026.
- Per Business Quant data, the three most recent Return on Invested Capital figures were 0.16% in Q1 2026, 0.23% in Q4 2025, and 0.25% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | OmniAb | 259.70 Mn | 210.62 Mn | 14.41 Mn | -0.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.16% |
| Dec 31, 2025 | -0.23% |
| Sep 30, 2025 | -0.25% |
| Jun 30, 2025 | -0.31% |
| Mar 31, 2025 | -0.32% |
| Dec 31, 2024 | -0.24% |
| Sep 30, 2024 | -0.18% |
| Jun 30, 2024 | -0.12% |
| Mar 31, 2024 | -0.09% |
| Dec 31, 2023 | -0.06% |
| Sep 30, 2023 | -0.03% |
| Jun 30, 2023 | -0.04% |
| Mar 31, 2023 | -0.04% |
| Dec 31, 2022 | -0.07% |